In view of the central importance of sympathetic hyperactivity in these cardiovascular diseases, the involvement of β2-AR/Giα signaling pathway in adverse vascular effects provides new insight into therapeutic approach for improvement of endothelial dysfunction and NO bioavailability. The gene discussed is ADRB2; the disease is endothelial dysfunction.